Recording from the ‘AI's Billion-dollar Bet on Life Sciences: From Drug Discovery to Patient Impact’ panel at Beryl Elites’ 7th Annual Investment Conference on November 4, 2025, in New York City, where Michael Heltzen, CEO, was featured as a panelist.
On the topic of applying AI in life sciences, CEO Michael Heltzen, said, "If I sat here as an investor, listening to us, what I would be thinking about is - what is actually going to end up as competitive advantages? Because if everyone is in an arms race, getting the same weapons, then you basically will have a status quo on power relationships. [...] That's why we, as a company, focus on where I think we will have the biggest impact relatively short term - and that is in drug discovery and drug development, where we're opening up for new chemistries that was not available to the world before."
Panel description
AI is moving beyond hype to deliver real-world breakthroughs in drug discovery and development. How Machine Learning is reshaping biopharma’s future. Showcasing case studies of AI-driven drugs and biomarkers, and confronting challenges like data bias, regulation, and scaling. Investors will gain actionable insights into the evolving AI-biotech landscape and where capital is flowing.
Panel moderator
- Wade Schulz, MD, PhD, Associate Professor, Yale University School of Medicine - Department of Pharmacology
Panel speakers
- Joy Wang, VP of Business Development & Strategy, Dendreon
- Sanjiv Koshal, Senior Director of Marketing Sciences, Gilead Sciences
- Sandy Balkin, SVP Strategy & Analytics, Royalty Pharma
- Frank Li, Founder & CEO, Stately Bio
- Michael Heltzen, CEO, eXoZymes
eXoZymes Safe Harbor
This video includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “potential,” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this video regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations
